Table 2.

Overview of selected MBT case reports and case series to date, including current study. Patient age, tumor stage, and PFS are reported as median values.

Authors	Year	Country	Cases reviewed	Age	Stage	Surgery (# pts)	Adjuvant treatment (# pts)	Clinical outcomes (# pts)b
Austin & Norris	1987	United States	16	60	IA	TAH, BSO (11); TAH, USO (2); USO (2); UO (1)	RT (2), RT + chemotherapya (1), none (14)	NED (9), DOD (5), DWED (2); PFS n/a
Gezginç, et al.	2011	Turkey	13	50	IIIC	TAH, BSO, omentectomy, LND (13)	CT (10), none (3)	AWD (7), NED (5), DWED; PFS 21 mo
Han, et al.	2014	South Korea	10	55.5	IA/IC	TAH, BSO, omentectomy, LND, appendectomy (8); USO (2)	CT (5), PT (1), none (4)	NED (6), AWD (1), DOD (2), DWED (1); PFS 16 mo
Lang, et al.	2017	United States	1	77	IIC	BSO, omentectomy, LND (1)c	CT (1)	NED (1); PFS 12 mo
Current study	2019	United States	10	64	IIA/IIB	TAH, BSO, Omentectomy, LND (4); TAH, BSO, Omentectomy (3); BSO, Omentectomy, LND (2); TAH, BSO (1)	CT (6), CT-NACT (1), CD (1), none (2)	NED (5), AWD (2), DOD (2), LTF (1); PFS 23 mod

Abbreviations – AWD: alive with disease; BSO: bilateral salpingo-oophorectomy; CD: carboplatin/docetaxel; CT: carboplatin/paclitaxel; DOD: died of disease; DWED: died without evidence of disease; LTF: lost to follow-up; LND: lymph node dissection; n/a: data not available for review; NACT: neoadjuvant chemotherapy; NED: no evidence of disease; PFS: progression-free survival; PT: cisplatin/paclitaxel; RT: radiation therapy; TAH: total abdominal hysterectomy; UO: unilateral oophorectomy; USO: unilateral salpingo-oophorectomy.

^aSpecific chemotherapy regimen was not reported.

^bOverall survival (OS) statistics were not uniformly reported through studies listed and thus not represented here.

^cPatient underwent prior hysterectomy for benign indication.

^dPFS calculation excludes one patient lost to follow-up immediately after initial surgery.